Check out the companies that made headlines during the day: Intel — The struggling chip stock rebounded toward the end of the year, rising 1.2%. Intel will plummet more than 60% in 2024, potentially giving the stock its worst year ever and the second-worst performance in the S&P 500. Nvidia — The artificial intelligence giant and retail investor favorite fell 2.3% as traders took profits as the trading year ended. With an increase of over 170%, Nvidia is poised to be the third-best performer on the S&P 500 in 2024. Hemophilia Gene Therapy Agreement A. Sangamo retained the rights to the product. Biohaven — The biopharmaceutical stock soared 4.4% after board member John Childs disclosed a purchase of 29,000 shares. Childs currently owns approximately 6.5 million shares. NutriBand — Shares rose 12.7% after NutriBand said it expects the review process for its abuse-deterrent opioid patch, AVERSA Fentanyl, to be expedited. This could allow the company to receive regulatory approval by the end of 2025. This comes as NutriBand last week extended its Chinese patent on the technology to Macau. Zivo Bioscience — Shares rose nearly 3% after investor Mark Strome, who owns a 10% stake in the biotechnology research and development company, bought 75,000 shares. —CNBC’s Sean Conlon, Yun Li and Pia Singh contributed reporting.
INTC, BHVN, NVDA etc.
